A traditional Chinese medicine composition, preparation, preparation method and application for improving prediabetes caused by internal heat and fullness in the middle jiao (spleen and stomach).
By using a specific ratio of traditional Chinese medicine composition and preparation process, the problem of insufficient targeting and poor compliance of existing traditional Chinese medicine compound prescriptions in the treatment of prediabetes with internal heat and fullness in the middle jiao is solved. It achieves the effect of comprehensive regulation of weight, blood sugar and blood lipids, and is suitable for long-term intervention in prediabetes with internal heat and fullness in the middle jiao.
Patent Information
- Application Number
- CN202611368572.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-04
- Publication Date
- 2026-11-17
AI Technical Summary
Existing Chinese herbal compound prescriptions lack specificity in treating prediabetes with internal heat and fullness in the middle jiao (spleen and stomach), making it difficult to achieve comprehensive effects in regulating weight, lowering blood sugar, and regulating blood lipids. Furthermore, long-term medication adherence is poor.
A traditional Chinese medicine composition consisting of herbs such as Bupleurum chinense, Cinnamomum cassia, Paeonia lactiflora, Trichosanthes kirilowii, Allium macrostemon, Citrus aurantium, Atractylodes lancea, Citrus reticulata, Magnolia officinalis, Atractylodes macrocephala, Poria cocos, Polyporus umbellatus, Alisma plantago-aquatica, Rehmannia glutinosa, Paeonia suffruticosa, Glycyrrhiza uralensis, Zingiber officinale, Coptis chinensis, Cinnamomum cassia, Astragalus membranaceus, and Pueraria lobata is prepared into granules or capsules for long-term intervention, based on the principles of regulating the middle jiao, dispersing fullness, clearing heat and resolving phlegm, combined with specific weight ratios and preparation processes.
It significantly reduced fasting blood glucose in prediabetic mice, improved oral glucose tolerance, regulated dyslipidemia, controlled weight gain, improved insulin resistance and liver function damage, and effectively regulated serum inflammatory factor levels, thus improving patient compliance.
Smart Images

Figure CN123101643A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, preparation, preparation method, and application for improving prediabetes caused by internal heat and fullness in the middle jiao (digestive system). Background Technology
[0002] Prediabetes refers to an intermediate state between normal and diabetic blood glucose levels, including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Epidemiological data show that the prevalence of prediabetes continues to rise, and it often coexists with obesity / overweight. Obesity is a significant risk factor for the progression from prediabetes to type 2 diabetes, and "diabetic obesity" has become a public health problem threatening human health.
[0003] In the field of Traditional Chinese Medicine (TCM), prediabetes falls under the categories of "spleen deficiency" and "diabetes mellitus." TCM theory holds that the core pathogenesis of obesity-related prediabetes is "internal heat and fullness in the middle jiao," caused by excessive consumption of rich and sweet foods and emotional imbalances leading to impaired spleen and stomach function, resulting in stagnation of spleen and liver qi, and internal heat due to stagnation in the middle jiao. Based on this, there is also the understanding that "six stagnations" (food, qi, blood, fire, phlegm, and dampness) combined with spleen deficiency constitute the disease. Currently, TCM prevention and treatment of prediabetes has formed a relatively systematic theoretical framework and clinical practice standards. The "Guidelines for Prediabetes Prevention and Intervention," published in 2025, is based on the TCM concept of "prevention of disease," integrating various intervention measures from both TCM and Western medicine, and systematically standardizing the TCM diagnosis and treatment of prediabetes. The concurrently published "Expert Consensus on the Integrated TCM and Western Medicine Treatment of Obesity-Diabetes" further standardizes the TCM differentiation, treatment principles, prescriptions, and health management of obesity-related diabetes. At the national level, the prevention and early intervention of diabetes with traditional Chinese medicine have also been included in the "Healthy China Action - Diabetes Prevention and Control Action Implementation Plan (2024-2030)," which clearly requires giving full play to the role of traditional Chinese medicine in "preventing disease" and promoting the application of guidelines for the prevention and intervention of prediabetes.
[0004] Regarding existing traditional Chinese medicine (TCM) compound prescriptions, there are already a number of patents and clinical reports on TCM compositions used for prediabetes and obesity-related metabolic disorders. For example, there are compound prescriptions formulated with the method of invigorating the spleen and relieving stagnation for overweight / obese prediabetes (spleen deficiency and phlegm dampness syndrome); there are TCM compositions with Coptis chinensis as the principal herb, targeting obese patients and those in the early "hot" state of diabetes; and there are also TCM compound prescriptions with the effects of lowering blood sugar and regulating lipids, which can improve abdominal obesity.
[0005] For example, the prior art CN108186636A discloses a pharmaceutical composition for treating prediabetes, which is composed of epiberberine, berberine, palmatine, berberine, astragaloside A, etc. This composition uses berberine alkaloids and astragalosides as the main active substances, focusing on exerting a hypoglycemic effect through a single group of components. Its shortcomings are: (1) This composition is a combination of effective parts or components of traditional Chinese medicine, lacking the guidance of the "principal, assistant, adjuvant and guide" theory of traditional Chinese medicine compound prescriptions, and it is difficult to reflect the holistic view of syndrome differentiation and treatment in traditional Chinese medicine; (2) This composition mainly targets the improvement of blood glucose indicators, and lacks a comprehensive intervention effect on multiple metabolic disorders such as overweight and dyslipidemia that coexist in obese prediabetic patients; (3) The extraction and purification process of its active ingredients is complicated, and the industrialization cost is high.
[0006] The prior art CN117137989A discloses a composition for treating type 2 diabetes and prediabetes and its preparation method, which includes a composition containing probiotics and traditional Chinese medicine ingredients. Its shortcomings are: (1) the composition mixes probiotics and traditional Chinese medicine ingredients, which raises the issue of stability in the compatibility of live bacteria preparations with traditional Chinese medicine extracts, and the preparation process is complex; (2) its formulation lacks a targeted design for the specific TCM pathogenesis of "internal heat and fullness in the middle jiao", and the treatment principle is not clear enough; (3) the storage and transportation conditions of probiotic products are relatively high, which limits their widespread application.
[0007] The prior art CN114392319A discloses a traditional Chinese medicine composition for treating prediabetes and its application, which is composed of Coptis chinensis, Astragalus membranaceus, Dioscorea opposita, Atractylodes lancea, Eupatorium fortunei, stir-fried Atractylodes macrocephala, Poria cocos, and Ophiopogon japonicus. The composition is based on the principle of tonifying the spleen and replenishing qi, clearing heat and drying dampness. Its shortcomings are: (1) The main treatment principle of this compound is to replenish qi and nourish yin, clear heat and generate fluids, but the symptoms of "three highs and one low" in obese prediabetic patients are not obvious. The core pathogenesis is "fullness and internal heat in the middle jiao" caused by stagnation in the middle jiao. This compound is not very targeted to this specific pathogenesis; (2) The composition contains only 8 herbs, and the combination is relatively simple. It lacks the overall regulation of the ascending, descending, entering and exiting of qi in the middle jiao; (3) It lacks comprehensive efficacy data to support weight control and blood lipid regulation.
[0008] The existing technology CN120437227A discloses a traditional Chinese medicine composition for treating prediabetes and its preparation method and application, which is similar to CN114392319A and consists of Coptis chinensis, Astragalus membranaceus, Dioscorea opposita, Atractylodes lancea, Eupatorium fortunei, stir-fried Atractylodes macrocephala, Poria cocos and Ophiopogon japonicus. Its shortcomings are: (1) It is also guided by the theory of "tonifying qi and strengthening spleen, clearing heat and drying dampness, nourishing yin and generating fluids", but it fails to accurately target the pathogenesis of "internal heat due to fullness in the middle jiao"; (2) It lacks an overall consideration of the ascending and descending of the spleen and stomach and the smooth flow of qi in the state of "internal heat due to fullness in the middle jiao"; (3) Its preparation process is conventional pulverization and mixing, wet granulation, and lacks optimization of key process parameters such as extraction, concentration and drying.
[0009] A clinical study on the use of Jianpi Chushi Granules in treating overweight / obese prediabetic patients (published in 2025). This study used Jianpi Chushi Granules to treat overweight / obese prediabetic patients. Its shortcomings are: (1) The formula takes Jianpi Chushi Granules as the main treatment method, focusing on the pathogenesis of "spleen deficiency and dampness trapping", and fails to fully cover the pathological outcome of "stagnation and heat" in "internal heat and fullness in the middle". (2) The formula lacks the combination of drugs that regulate Qi and clear internal heat. (3) The study is mainly based on clinical observation and lacks systematic animal experimental pharmacodynamic data support.
[0010] In addition, there are already traditional Chinese medicines on the market such as Kele Ning Capsules, Xiaoke Kang Granules, and Jiangtang Shu Capsules for the early stages of diabetes. Their formulas mainly focus on invigorating qi and nourishing yin, clearing heat and promoting body fluid production.
[0011] Based on the analysis of existing technologies, the following shortcomings exist in the current treatment of prediabetes (obese / moderate type): 1. There is a lack of specific formulas targeting the core pathogenesis of "internal heat and fullness in the middle jiao". Most existing Chinese patent medicines and compound Chinese herbal formulas for treating prediabetes focus on tonifying qi and nourishing yin, clearing heat and generating fluids. However, the "three highs and one low" symptoms (polyuria, polydipsia, polyphagia, and weight loss) are often not obvious in obese prediabetic patients. The core pathogenesis lies in "internal heat and fullness in the middle jiao" caused by stagnation in the middle jiao, and treatment should focus on regulating the middle jiao, dispersing fullness, clearing heat and resolving phlegm. Existing compound formulas are not highly targeted at this specific pathogenesis, making it difficult to achieve precise diagnosis and treatment.
[0012] 2. The comprehensive effect of regulating glucose and lipid metabolism and weight needs improvement. Existing traditional Chinese medicine formulas mostly focus on lowering blood sugar or improving insulin resistance, with limited effectiveness in addressing the multiple metabolic disorders present in obese prediabetic patients, such as overweight and dyslipidemia. Clinically, there is an urgent need for a traditional Chinese medicine composition that can simultaneously achieve a comprehensive therapeutic effect of controlling weight, lowering blood sugar, and regulating blood lipids.
[0013] 3. Insufficient clinical adherence to long-term medication. Prediabetes requires long-term intervention to delay or prevent its progression to diabetes. However, some existing traditional Chinese medicine compound prescriptions have problems such as poor taste (due to excessive use of bitter and cold herbs), large dosages, and numerous adverse reactions, resulting in poor patient adherence to long-term medication. How to improve the acceptability and safety of these preparations while ensuring efficacy is an important issue currently facing us.
[0014] 4. The formulation and compatibility of existing compound prescriptions are not yet perfect. Some traditional Chinese medicine compound prescriptions with existing patents or clinical reports are not yet perfect in terms of the rigor of compatibility and the hierarchical relationship of the principal, assistant, adjuvant, and guide herbs. They lack a holistic consideration of the ascending and descending functions of the spleen and stomach and the smooth flow of qi in the pathological state of "spleen fullness".
[0015] In other words, the existing technology does not have enough traditional Chinese medicine compound prescriptions for the specific syndrome of "obesity-oriented prediabetes with fullness and internal heat in the middle jiao" that use the principles of regulating the middle jiao, dispersing fullness, clearing heat and resolving phlegm. Moreover, most existing compound prescriptions still have room for improvement in terms of comprehensive efficacy in controlling weight, lowering blood sugar and blood lipids, and clinical compliance with long-term medication. Summary of the Invention
[0016] To address the above-mentioned technical problems, the primary objective of this invention is to provide a traditional Chinese medicine composition for improving prediabetes characterized by internal heat and fullness in the middle burner. This composition is made from Bupleurum chinense, Cinnamomum cassia, Paeonia lactiflora, Trichosanthes kirilowii, Allium macrostemon, Citrus aurantium, Atractylodes lancea, Citrus reticulata peel, Magnolia officinalis, Atractylodes macrocephala, Poria cocos, Polyporus umbellatus, Alisma plantago-aquatica, Rehmannia glutinosa, Paeonia suffruticosa, Glycyrrhiza uralensis, Zingiber officinale, Coptis chinensis, Cinnamomum cassia, Astragalus membranaceus, and Pueraria lobata in a specific weight ratio. This invention's composition, based on the principles of regulating the middle burner, dispersing fullness, clearing heat, and resolving phlegm, precisely targets the core pathogenesis of "internal heat and fullness in the middle burner." It has the effects of regulating the Qi of the middle burner, clearing internal heat, strengthening the spleen, promoting diuresis, and resolving phlegm, aiming to achieve a comprehensive therapeutic effect of controlling weight, lowering blood sugar, and regulating blood lipids.
[0017] The second objective of this invention is to provide an application of a formulation for improving prediabetes of the "internal heat and fullness" type in the preparation of drugs to improve prediabetic symptoms. Pharmacodynamic experiments in this application demonstrate that the composition can significantly reduce fasting blood glucose in prediabetic mice, improve oral glucose tolerance, regulate dyslipidemia, control weight gain, improve insulin resistance and liver function damage, and effectively regulate serum inflammatory factor levels. This invention features a rigorous formulation, appropriate compatibility, high safety, and good patient compliance, making it suitable for long-term intervention in prediabetes of the "internal heat and fullness" type and possessing broad application prospects.
[0018] To achieve the above objectives, the present invention adopts the following technical solution: A traditional Chinese medicine composition for improving prediabetes caused by internal heat and fullness in the middle jiao (digestive system), comprising the following raw materials in parts by weight: Bupleurum chinense 8-16 parts, Cinnamomum cassia 7-13 parts, Paeonia lactiflora 7-13 parts, Trichosanthes kirilowii 7-13 parts, Allium macrostemon 7-13 parts, Citrus aurantium 7-13 parts, Atractylodes lancea 7-13 parts, Citrus reticulata 7-13 parts, Magnolia officinalis 7-13 parts, Atractylodes macrocephala 7-13 parts, Poria cocos 7-13 parts, Polyporus umbellatus 7-13 parts, Alisma plantago-aquatica 7-13 parts, Rehmannia glutinosa 20-40 parts, Paeonia suffruticosa 7-13 parts, Glycyrrhiza uralensis 7-13 parts, Zingiber officinale 3-7 parts, Coptis chinensis 7-13 parts, Cinnamomum cassia 2-4 parts, Astragalus membranaceus 10-20 parts, and Pueraria lobata 10-20 parts.
[0019] The formulation principle and compatibility explanation of the above-mentioned traditional Chinese medicine composition: The formulation of this invention is guided by the traditional Chinese medicine theory of "internal heat and fullness in the middle jiao," and its treatment principle is to regulate the middle jiao, dispel fullness, clear heat, and resolve phlegm. The entire formula consists of 21 herbs, with clear distinctions between the principal, assistant, adjuvant, and guiding herbs. The principal herbs are Bupleurum and Cinnamon Twig: Bupleurum disperses and drains, soothes the liver and relieves stagnation, and raises the clear yang, thus regulating the qi mechanism of the triple burner from the perspective of ascending and descending; Cinnamon Twig disperses and warms, warms the yang and transforms qi, and promotes blood circulation, thus improving the qi transformation of the internal organs from the perspective of nutritive and defensive qi. Together, they serve as the principal herbs, targeting the core pathogenesis of metabolic diseases caused by stagnation and dysfunction of the pivot, and regulating glucose and lipid metabolism.
[0020] The accompanying herbs—Poria cocos, Atractylodes macrocephala, Atractylodes lancea, Astragalus membranaceus, and Pueraria lobata—work together to invigorate the spleen and eliminate dampness. Atractylodes macrocephala strengthens the spleen and promotes the upward movement of clear qi. Atractylodes lancea dries dampness and reduces turbidity. These three herbs work synergistically to strengthen the spleen and eliminate dampness, addressing the pathological basis of spleen deficiency and dampness accumulation, and phlegm generation in metabolic diseases, while also assisting Cinnamomum cassia in warming yang and resolving phlegm. Astragalus membranaceus tonifies the middle qi; Pueraria lobata promotes yang and generates fluids. Both tonify qi and promote yang, distributing body fluids and improving the metabolic disorder characterized by "failure of clear yang to ascend and failure of turbid yin to descend."
[0021] The adjuvant herbs—Trichosanthes kirilowii, Allium macrostemon, Citrus aurantium, Magnolia officinalis, Coptis chinensis, Paeonia suffruticosa, Rehmannia glutinosa, Paeonia lactiflora, Polyporus umbellatus, and Alisma plantago-aquatica: Trichosanthes kirilowii and Allium macrostemon promote yang, disperse stagnation, relieve chest congestion, and resolve phlegm, addressing the symptoms of phlegm stagnation in the chest and epigastrium associated with metabolic diseases, and preventing cardiovascular complications; Citrus aurantium and Magnolia officinalis promote bowel movement, relieve fullness, reduce turbidity, and regulate the qi mechanism of the middle jiao; Coptis chinensis clears heat and reduces stagnation, while Paeonia suffruticosa cools the blood, disperses blood stasis, clears stagnant heat, and resolves turbidity, restraining the warm and dry nature of the entire formula, addressing the pathological outcome of "prolonged stagnation leading to heat" in metabolic diseases; Rehmannia glutinosa and Paeonia lactiflora nourish yin, reduce stagnation, nourish yin and soften the liver, and prevent yin damage from warm dryness, addressing the pathogenesis of "dryness and heat damaging body fluids" in metabolic diseases; Polyporus umbellatus and Alisma plantago-aquatica promote diuresis, expelling dampness and turbidity from the lower jiao, forming a water-regulating pattern in combination with Poria cocos and Atractylodes macrocephala.
[0022] The guiding herbs—licorice root, cinnamon, and dried ginger—harmonize the other herbs, balance their hot and cold properties, alleviate urgency, and harmonize the overall balance of the formula. Cinnamon guides the fire back to its source, while dried ginger warms the middle and dispels cold. The small amounts of these herbs are chosen to "generate life with a little fire," warming and tonifying the fire of the gate of life (Mingmen), assisting cinnamon twig in promoting yang and transforming qi, warming and unblocking the meridians, and preventing cold herbs like Coptis chinensis from damaging yang.
[0023] Preferably, it is composed of the following parts by weight of active pharmaceutical ingredient: Bupleurum chinense 12 parts, Cinnamomum cassia 10 parts, Paeonia lactiflora 10 parts, Trichosanthes kirilowii 10 parts, Allium macrostemon 10 parts, Citrus aurantium 10 parts, Atractylodes lancea 10 parts, Citrus reticulata 10 parts, Magnolia officinalis 10 parts, Atractylodes macrocephala 10 parts, Poria cocos 10 parts, Polyporus umbellatus 10 parts, Alisma plantago-aquatica 10 parts, Rehmannia glutinosa 30 parts, Paeonia suffruticosa 10 parts, Glycyrrhiza uralensis 10 parts, Zingiber officinale 5 parts, Coptis chinensis 10 parts, Cinnamomum cassia 3 parts, Astragalus membranaceus 15 parts, and Pueraria lobata 15 parts.
[0024] An preparation for improving prediabetes of the type characterized by internal heat and fullness in the middle jiao (digestive system), comprising the aforementioned traditional Chinese medicine composition.
[0025] A method for preparing a formulation to improve prediabetes of the central nervous system with internal heat includes the following steps: S1. Pretreatment and Grinding: Weigh each raw material according to the formula, clean and remove impurities, dry and mix evenly, then pulverize and set aside. S2, Extraction: Place the weighed raw materials in an extraction container, add 6 to 12 times the total weight of the medicinal materials in water, soak for 0.5 to 2.5 hours, heat to boiling, and simmer for 1.5 to 2.5 hours. Filter and collect the first extract. Add 4 to 8 times the total weight of the medicinal materials in water to the dregs again, continue to simmer for 1 to 2 hours, and filter and collect the second extract. S3. Concentration and Drying: Combine the two extracts, allow them to stand and precipitate, take the supernatant or filter, concentrate the filtrate to a thick paste or clear paste with a relative density of 1.10 to 1.20 under conditions of -0.08 to -0.06 MPa and 50 to 70℃, and spray dry it with an inlet air temperature of 160 to 190℃ and an outlet air temperature of 70 to 85℃ to obtain dry extract powder; S4, Molding: The dry extract powder is mixed with excipients, a wetting agent is added to form a soft material, which is then granulated, dried, and sized to obtain the final product.
[0026] Preferably, in step S1, the material is pulverized and then passed through an 80-100 mesh sieve. In step S2, the first decoction is prepared by adding 10 times the amount of water, soaking for 2 hours, and then decocting for 2 hours; the second decoction is prepared by adding 8 times the amount of water and decocting for 1.5 hours.
[0027] Preferably, in step S4, the excipients include any one of dextrin, starch, and lactose; The dry extract powder and excipients are mixed at a mass ratio of 1:0.8~1.2; The wetting agent is ethanol with a mass fraction of 70-90%; The granulation process involves passing the pellet through a 12-14 mesh filter sieve. The drying temperature is 55~65℃.
[0028] Application of a formulation for improving prediabetes caused by internal heat and fullness in the preparation of drugs for improving prediabetes symptoms.
[0029] Preferably, the improvement of prediabetes symptoms includes reducing fasting blood glucose in prediabetic mice, improving oral glucose tolerance, regulating dyslipidemia, controlling weight gain, improving insulin resistance and liver function damage, and regulating serum inflammatory factor levels.
[0030] Preferably, the regulation of serum inflammatory factor levels includes inhibiting the excessive secretion of pro-inflammatory factors such as TNF-α, IL-6, IL-1β, IL-12p70, and IL-17A; and restoring the levels of anti-inflammatory factors such as IL-2, IL-4, IL-5, and IL-10.
[0031] Compared with the prior art, the present invention has at least the following technical effects: This invention provides a traditional Chinese medicine composition for improving prediabetes caused by internal heat and fullness in the middle jiao. The composition is made up of Bupleurum chinense, Cinnamomum cassia, Paeonia lactiflora, Trichosanthes kirilowii, Allium macrostemon, Citrus aurantium, Atractylodes lancea, Citrus reticulata, Magnolia officinalis, Atractylodes macrocephala, Poria cocos, Polyporus umbellatus, Alisma plantago-aquatica, Rehmannia glutinosa, Paeonia suffruticosa, Glycyrrhiza uralensis, Zingiber officinale, Coptis chinensis, Cinnamomum cassia, Astragalus membranaceus, and Pueraria lobata in a specific weight ratio. The traditional Chinese medicine composition of this invention is based on the principles of regulating the middle burner, dispersing fullness, clearing heat and resolving phlegm. It precisely targets the core pathogenesis of "fullness in the middle burner and internal heat". In the formula, Bupleurum, Fructus Aurantii Immaturus, and Cortex Magnoliae Officinalis regulate the Qi of the middle burner to disperse fullness in the middle burner. Coptis, Fructus Trichosanthis, and Cortex Moutan clear internal heat. Atractylodes lancea, Rhizoma Atractylodis Macrocephalae, Poria, Polyporus umbellatus, and Rhizoma Alisma plantago-aquatica strengthen the spleen and promote diuresis to resolve phlegm and turbidity. It is consistent with the core pathogenesis of obesity-related prediabetes and has the effects of regulating the Qi of the middle burner, clearing internal heat, strengthening the spleen, promoting diuresis and resolving phlegm and turbidity. It aims to achieve a comprehensive therapeutic effect of "three-in-one" of controlling weight, lowering blood sugar and regulating blood lipids.
[0032] The application of this formulation for improving prediabetes caused by internal heat and fullness in the preparation of drugs to improve prediabetes symptoms. Pharmacodynamic experiments in this application demonstrate that the composition, through multi-target and multi-process synergistic effects, can improve dyslipidemia and control weight while lowering blood glucose, achieving overall regulation of metabolic syndrome and comprehensively improving glucose and lipid metabolism and weight; it significantly reduces fasting blood glucose in prediabetic mice, improves oral glucose tolerance, regulates dyslipidemia, controls weight gain, improves insulin resistance and liver function damage, and can effectively regulate serum inflammatory factor levels.
[0033] The formula of this invention has mild medicinal properties, combining both cold and warm properties (such as dried ginger and cinnamon to counteract the cold properties of Coptis chinensis and peony bark), and has good safety for long-term use. The formula contains 21 herbs, covering multiple effects such as soothing the liver and regulating qi, strengthening the spleen and resolving dampness, clearing heat and purging fire, and warming yang and promoting qi circulation. The roles of the principal, assistant, adjuvant, and guide herbs are clearly defined, reflecting the advantages of the holistic concept and syndrome differentiation and treatment in traditional Chinese medicine. It has high safety, good patient compliance, and is suitable for long-term intervention of prediabetes with internal heat and fullness in the middle jiao, and has broad application prospects. Attached Figure Description
[0034] Figure 1 The curve of mouse body weight change after intervention with the finished product was prepared for Example 1; Figure 2 A graph showing the change in food intake in mice after the intervention of the finished product in Example 1 was prepared. Figure 3 The graph shows the changes in fasting blood glucose in mice after the treatment with the finished product in Example 1. Figure 4 The graph shows the changes in oral glucose tolerance in mice after the intervention of the finished product in Example 1. Figure 5 The graph shows the changes in insulin resistance in mice after intervention with the finished product prepared in Example 1. Figure 6 The graph shows the changes in blood lipids in mice after the treatment with the prepared product in Example 1. Figure 7 The graph shows the changes in liver function in mice after the treatment with the prepared product in Example 1. Figure 8 The graph shows the changes in serum inflammatory factors in mice after intervention with the finished product prepared in Example 1. Figure 9 The images show the liver samples taken from mice in each group after the intervention in Example 1, along with the results of HE staining and Oil Red O staining. Figure 10 The high-performance liquid chromatograms of the test solution and the reference solution of the particulate sample in Example 1 are shown. Detailed Implementation
[0035] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the present invention will be briefly introduced below in conjunction with the accompanying drawings and descriptions of the embodiments or the prior art. Obviously, the following description of the structure of the accompanying drawings is only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort. It should be noted that the description of these embodiments is for the purpose of helping to understand the present invention, but does not constitute a limitation of the present invention.
[0036] One specific embodiment of the present invention is as follows: A traditional Chinese medicine composition for improving prediabetes caused by internal heat and fullness in the middle jiao (digestive system), comprising the following raw materials in parts by weight: Bupleurum chinense 8-16 parts by weight; Cinnamomum cassia 7-13 parts by weight; Paeonia lactiflora 7-13 parts by weight; Trichosanthes kirilowii 7-13 parts by weight; Allium macrostemon 7-13 parts by weight; Citrus aurantium 7-13 parts by weight; Atractylodes lancea 7-13 parts by weight; Citrus reticulata 7-13 parts by weight; Magnolia officinalis 7-13 parts by weight; Atractylodes macrocephala 7-13 parts by weight; Poria cocos 7-13 parts by weight; Polyporus umbellatus 7-13 parts by weight; Alisma plantago-aquatica 7-13 parts by weight; Rehmannia glutinosa 20-40 parts by weight; Paeonia suffruticosa 7-13 parts by weight; Glycyrrhiza uralensis 7-13 parts by weight; Zingiber officinale 3-7 parts by weight; Coptis chinensis 7-13 parts by weight; Cinnamomum cassia 2-4 parts by weight; Astragalus membranaceus 10-20 parts by weight; Pueraria lobata 10-20 parts by weight.
[0037] A method for preparing a traditional Chinese medicine preparation for improving prediabetes of the type characterized by internal heat and fullness in the middle jiao (spleen and stomach) includes the following steps: (taking solid dosage forms, such as granules, capsules, or tablets, as an example): (1) Pretreatment and pulverization: Weigh each raw material according to the above ratio, clean and remove impurities, dry and mix evenly, and pulverize into fine powder (pass through an 80-100 mesh sieve); or according to clinical needs, do not pulverize and use directly for decoction.
[0038] (2) Extraction (preferably water extraction): Place the weighed raw materials in an extraction container, add 6-12 times the total weight of the materials in water, and soak for 0.5-2.5 hours. Then heat to boiling, maintain a gentle boil and simmer for 1.5-2.5 hours, filter and collect the first extract. Add 4-8 times the total weight of the materials in water to the residue again, continue to simmer for 1-2 hours, filter and collect the second extract.
[0039] (3) Concentration and drying: Combine the two extracts, allow them to stand and precipitate, and take the supernatant or filter. Concentrate the filtrate under reduced pressure (-0.08~-0.06MPa) and temperature of 50~70℃ to a thick paste or clear paste with a relative density of 1.10~1.20 (measured at 60℃). Spray dry the obtained clear paste (inlet air temperature 160~190℃, outlet air temperature 70~85℃) to obtain dry extract powder.
[0040] (4) Formulation (taking granules as an example): The dry extract powder obtained in step (3) is mixed with excipients (such as dextrin, starch, lactose, etc.) at a mass ratio of 1:1.1, and an appropriate amount of wetting agent (such as 70%~90% ethanol) is added to form a soft material. The material is then granulated by passing it through a 12~14 mesh sieve, dried at 55~65℃, and granulated to obtain the Chinese medicine granules of this invention.
[0041] Note: When using as a decoction, place the raw materials in the above proportions in a decoction pot, add water to cover the herbs by 2-3 cm, soak for 30 minutes, bring to a boil over high heat, then simmer over low heat for 25-35 minutes, filter out the liquid; add water to the dregs and decoct for another 20-30 minutes, combine the two liquids, and take warm twice a day, morning and evening.
[0042] Example 1: A traditional Chinese medicine composition for improving prediabetes caused by internal heat and fullness in the middle jiao (digestive system), comprising the following raw materials in parts by weight: Bupleurum chinense 12g, Cinnamomum cassia 10g, Paeonia lactiflora 10g, Trichosanthes kirilowii 10g, Allium macrostemon 10g, Citrus aurantium 10g, Atractylodes lancea 10g, Citrus reticulata 10g, Magnolia officinalis 10g, Atractylodes macrocephala 10g, Poria cocos 10g, Polyporus umbellatus 10g, Alisma plantago-aquatica 10g, Rehmannia glutinosa 30g, Paeonia suffruticosa 10g, Glycyrrhiza uralensis 10g, Zingiber officinale 5g, Coptis chinensis 10g, Cinnamomum cassia 3g, Astragalus membranaceus 15g, Pueraria lobata 15g.
[0043] A method for preparing a traditional Chinese medicine preparation for improving prediabetes of the type characterized by fullness and internal heat includes the following steps (taking a decoction as an example): Place the raw materials in the above proportions into a decoction pot, add 8 times the amount of water to cover the surface of the herbs by 2-3 cm, soak for 30 minutes, bring to a boil over high heat, then simmer over low heat for 40 minutes, filter out the liquid; add water to the dregs and decoct for another 40 minutes, combine the two liquids, and concentrate to 6g / mL.
[0044] Example 2: The formulation and compatibility are the same as in Example 1.
[0045] A method for preparing a traditional Chinese medicine preparation for improving prediabetes of the type characterized by internal heat and fullness in the middle jiao (spleen and stomach), comprising the following steps (taking a solid granule preparation as an example): (1) Pretreatment and pulverization: Weigh each raw material according to the above ratio, clean and remove impurities, dry and mix evenly, and pulverize into fine powder (pass through a 100-mesh sieve);
[0046] (2) Extraction (water extraction): Place the weighed raw materials in an extraction container, add water at 10 times the total weight of the materials, and soak for 2 hours. Then heat to boiling, maintain a gentle boil and decoct for 2 hours, filter and collect the first extract. Add water at 8 times the total weight of the materials to the residue again, continue to decoct for 1.5 hours, filter and collect the second extract.
[0047] (3) Concentration and drying: Combine the two extracts, allow them to stand and precipitate, and take the supernatant or filter. Concentrate the filtrate under reduced pressure (-0.07 MPa) and at 60°C to a thick paste or clear paste with a relative density of 1.10~1.20 (measured at 60°C). Spray dry the obtained clear paste (inlet air temperature 180°C, outlet air temperature 80°C) to obtain dry extract powder.
[0048] (4) Formulation: The dry extract powder obtained in step (3) is mixed with excipients (dextrin) at a mass ratio of 1:1.1, 85% ethanol is added to form a soft mass, which is then granulated through a 14-mesh sieve, dried at 60°C, and granulated to obtain the Chinese medicine granules of this invention.
[0049] Example 3: A traditional Chinese medicine composition for improving prediabetes caused by internal heat and fullness in the middle jiao (digestive system), comprising the following raw materials in parts by weight: Bupleurum chinense 8g, Cinnamomum cassia 7g, Paeonia lactiflora 7g, Trichosanthes kirilowii 7g, Allium macrostemon 7g, Citrus aurantium 7g, Atractylodes lancea 7g, Citrus reticulata 7g, Magnolia officinalis 7g, Atractylodes macrocephala 7g, Poria cocos 7g, Polyporus umbellatus 7g, Alisma plantago-aquatica 7g, Rehmannia glutinosa 20g, Paeonia suffruticosa 7g, Glycyrrhiza uralensis 7g, Zingiber officinale 3g, Coptis chinensis 7g, Cinnamomum cassia 2g, Astragalus membranaceus 10g, Pueraria lobata 10g.
[0050] Example 4: A traditional Chinese medicine composition for improving prediabetes caused by internal heat and fullness in the middle jiao (digestive system), comprising the following raw materials in parts by weight: Bupleurum chinense 16g, Cinnamomum cassia 13g, Paeonia lactiflora 13g, Trichosanthes kirilowii 13g, Allium macrostemon 13g, Citrus aurantium 13g, Atractylodes lancea 13g, Citrus reticulata 13g, Magnolia officinalis 13g, Atractylodes macrocephala 13g, Poria cocos 13g, Polyporus umbellatus 13g, Alisma plantago-aquatica 13g, Rehmannia glutinosa 40g, Paeonia suffruticosa 13g, Glycyrrhiza uralensis 13g, Zingiber officinale 7g, Coptis chinensis 13g, Cinnamomum cassia 4g, Astragalus membranaceus 20g, Pueraria lobata 20g.
[0051] Validation experiment: Pharmacodynamic experiment 1. Laboratory animals and environment Male SPF-grade C57BL / 6J mice, 6-8 weeks old and weighing 18-20g, were selected and divided into 6 mice per cage. The ambient temperature was 22-23℃, and the humidity was 55%-60%. The daily light / dark cycle was 12h / 12h. All experimental procedures and blood glucose tests were conducted in a quiet, temperature-controlled environment and at the same time whenever possible.
[0052] 2. Animal modeling After one week of adaptive feeding, mice were randomly divided into a control group (NC, n=24) and a high-fat group (HFD, n=72) based on body weight. This model was induced using a simple high-fat diet. The high-fat group was fed a high-fat diet (Research Diets, D12492 / Fat 60kcal%), while the control group was fed a control diet (Research Diets, D12450J / Fat 10kcal%). Based on changes in blood glucose levels, weeks 6 and 16 (the endpoint) were selected as sampling points. Prediabetes was successfully established at week 6. Successful model establishment criteria included: increased body weight, fasting blood glucose less than 7.0 mmol / L, and 7.8 mmol / L ≤ 2h OGTT < 11.1 mmol / L.
[0053] 3. Grouping and Dosing Six weeks later, after successful establishment of the prediabetes model, mice were randomly divided into the following 5 groups (n=12): Model group, low-dose group of Example 1 (CDF-L, 15g / kg / d), medium-dose group of Example 1 (CDF-M, 30g / kg / d), high-dose group of Example 1 (CDF-H, 60g / kg / d), and positive control group (JQJTP, Jinqi hypoglycemic tablets, 1 tablet 0.56g, 3 tablets each time, 3 times a day. The equivalent dose is 0.655g / kg / d). The above groups continued to be fed a high-fat diet, while the NC group (n=12) continued to be fed a control diet. The gavage volume of the corresponding drug was calculated based on the weekly body weight of the mice (0.1mL / 10g), and the mice were administered the drug once a day for 10 consecutive weeks. Blood glucose was measured by collecting blood samples from the tail tip every 2 weeks, and samples were collected after any discrepancies were found.
[0054] Table 1. Drug administration and feed details for each group.
[0055] 4. Preparation of the test sample drug stock solution (230 g crude drug) The test sample was a concentrated decoction of a compound herb consisting of Bupleurum chinense, Cinnamomum cassia, Paeonia lactiflora, Trichosanthes kirilowii, Allium macrostemon, Citrus aurantium, Atractylodes lancea, Citrus reticulata, Magnolia officinalis, Atractylodes macrocephala, Poria cocos, Polyporus umbellatus, Alisma plantago-aquatica, Rehmannia glutinosa, Paeonia suffruticosa, Glycyrrhiza uralensis, Zingiber officinale, Coptis chinensis, Cinnamomum cassia, Astragalus membranaceus, and Pueraria lobata, measured according to the "raw drug equivalent"; the negative control was CMC-Na; the human baseline dose (1 time) was defined as 70 kg for adults. Bupleurum chinense 12 g, Cinnamomum cassia 10 g, Paeonia lactiflora 10 g, Trichosanthes kirilowii 10 g, Allium macrostemon 10 g, Citrus aurantium 10 g, Atractylodes lancea 10 g, Citrus reticulata 10 g, Magnolia officinalis 10 g, Atractylodes macrocephala 10 g, Poria cocos 10 g, Polyporus umbellatus 10 g, Alisma plantago-aquatica 10 g, Rehmannia glutinosa 30 g, Paeonia suffruticosa 10 g, Glycyrrhiza uralensis 10 g, Zingiber officinale 5 g, Coptis chinensis 10 g, Cinnamomum cassia 3 g, Astragalus membranaceus 15 g, Pueraria lobata 15 g. In Example 1, the total amount of raw herbs in the prescription was 230g. The herbs were soaked in approximately 1840mL (8 times the volume of the original liquid) of cold water for 30 minutes, then boiled and simmered for 40 minutes. The first decoction was collected by filtration. The dregs were then boiled in approximately 1840mL (8 times the volume of the original liquid) of cold water, boiled again, and simmered for another 40 minutes. The second decoction was collected by filtration. The two filtrates were combined and concentrated to 6 g / mL. The mother liquor was equivalent to the concentration of the high-dose group. The mother liquor was dispensed and stored at -20℃. Before use, it was thawed at 4℃ and thoroughly mixed to avoid fluctuations in composition caused by repeated freeze-thaw cycles.
[0056] 5. Observation Indicators and Detection Methods 5.1 Monitoring of body weight, food intake, and general condition Changes in mouse weight and food intake were recorded at fixed times each week. The mental state, coat luster, and activity levels of the mice in each group were observed.
[0057] 5.2 Fasting blood glucose and oral glucose tolerance test Fasting blood glucose (FBG) was measured in mice at fixed times each week, and oral glucose tolerance test (OGTT) was performed at the end of week 6 and week 16.
[0058] FBG measurement method: After fasting for 12 hours with free access to water, blood glucose was measured by collecting blood from the tail tip. Mice were placed in individual cages, secured with their tails exposed, and the tail tip was disinfected with an iodine-soaked cotton ball. The tail was then cut with medical scissors to draw a small amount of blood, which was dripped onto a blood glucose test strip inserted into the meter, and the FBG was measured. The tail tip was then disinfected with iodine and returned to the original cage.
[0059] OGTT method: Fasting for 12 hours with free access to water, administer 20 mg / 10 g. -1 20% glucose was administered by gavage, and fasting blood glucose (FBG) was measured at 0, 15, 30, 60, 90, and 120 min. OGTT curves were plotted, and the area under the curve (AUC) was calculated.
[0060] 5.3 Measurement of blood lipids, liver function, serum insulin, and serum inflammatory factors At weeks 6 and 16 post-modeling, blood was collected from the orbital sinus of mice and placed into ordinary centrifuge tubes. After standing at room temperature for 1 hour, the tubes were centrifuged at 2000 g for 15 min at 4°C. The supernatant serum was carefully aspirated by pipette, and the levels of TG, TC, LDL-C, HDL-C, ALT, AST, insulin (HOMA-IR and HOMA-β indices were calculated), IL-2, IL-4, IL-5, IL-6, IL-10, IL-17A, IL-12p70, IL-1β, IFN-γ, and TNF-α in the serum were measured according to the kit instructions.
[0061] 5.4 Liver histopathological examination Pathological examination of mouse liver tissue was performed. The specific procedures are as follows: ① HE staining: Mouse tissues were rapidly fixed in 4% paraformaldehyde solution for 24 hours. After fixation, the tissues were dehydrated using a series of ethanol solutions, cleared with xylene, and then embedded in paraffin. The paraffin blocks were cut into continuous sections of 4–5 μm thickness using a microtome and attached to anti-detachment slides. After dewaxing to water using xylene, the sections were stained sequentially with hematoxylin (to stain the cell nuclei), briefly differentiated with hydrochloric acid ethanol, and then blued with running water. Subsequently, cytoplasmic staining was performed using eosin. Finally, the sections were dehydrated using a series of ethanol solutions, cleared with xylene, and mounted with neutral resin. Images were observed and acquired under an optical microscope to assess the tissue structure, morphology, and pathological damage.
[0062] ② Oil Red O staining: Lipid observation was performed using frozen sections. Mouse tissues were fixed with 4% paraformaldehyde and then subjected to gradient dehydration in 15% and 30% sucrose solutions. After embedding the tissues with OCT embedding medium, they were cut into 8–10 μm thick sections using a cryostat. After drying at room temperature, the sections were stained with Oil Red O working solution in the dark for 10–15 min, followed by brief differentiation with 60% isopropanol to remove background staining, and then washed with water. The cell nuclei were counterstained with hematoxylin and the stain was returned to blue with running water. Finally, the sections were mounted with glycerol gelatin. Under an optical microscope, neutral lipid droplets in the tissue appeared orange-red to bright red, and the cell nuclei appeared blue.
[0063] 6. Preparation and dilution of working solution When the gavage volume is 10 mL / kg, the target working solution concentrations for each dose group are 6 g / mL for high dose, 3 g / mL for medium dose, and 1.5 g / mL for low dose. The working solution is prepared from the stock solution, with 25-30 mL prepared fresh for each group per week to reduce contamination and waste (for example, prepare 30 mL per group: for high dose, take 30 mL of stock solution and make up to 30 mL; for medium dose, take 15 mL of stock solution and make up to 30 mL; for low dose, take 7.5 mL of stock solution and make up to 30 mL). The working solution should be stored at 4°C for no more than 7 days and mixed well before each administration.
[0064] 7. Statistical Judgment Data processing, analysis, and graphing were performed using SPSS 26.0 and GraphPad Prism 10.0. The results are expressed as mean ± standard deviation. The expression (±s) indicates that when comparing two groups, an independent samples t-test is used if the distribution is normal and the variances are homogeneous; otherwise, the Mann-Whitney U test is used. When comparing multiple groups, one-way ANOVA is used if the distribution is normal and the variances are homogeneous; otherwise, the Kruskal-Wallis H test is used. All statistical analyses use two-tailed tests. P <0.05 indicates a statistically significant difference.
[0065] 8. Determination of the content of index components in the finished product prepared in Example 1 Traditional Chinese medicine compound preparations possess unique advantages in clinical efficacy due to their multi-component and multi-target action characteristics. However, the complexity of their chemical composition and batch-to-batch variability also pose challenges to quality control. Quality standards, as the core guarantee throughout the entire chain of preparation research and development, production, and clinical application, are directly related to the safety, efficacy, and quality uniformity of drugs. Therefore, establishing scientific, reliable, and easy-to-operate content determination methods is of great significance for clarifying the key pharmacodynamic material basis of preparations and achieving full-process quality traceability.
[0066] High-performance liquid chromatography (HPLC), with its advantages of high separation efficiency, good reproducibility, superior detection sensitivity, and wide applicability, has become the mainstream technique for the quantitative analysis of active ingredients in traditional Chinese medicine and its preparations. This method can effectively separate target components in complex matrices and achieve accurate quantification using detectors such as ultraviolet light, diode arrays, or evaporative light scattering, providing solid methodological support for the quality evaluation of preparations.
[0067] This project takes the granules of Example 1 as the research object, and establishes and optimizes the HPLC content determination method for its main index components. Through actual measurement of multiple batches of samples, the fluctuation of component content of the preparation is comprehensively evaluated, providing experimental basis for the formulation of reasonable quality control standards, and laying the foundation for subsequent in-depth research on the pharmacodynamic material basis and the exploration of the mechanism of action.
[0068] 8.1 Example 1 Particle Preparation Method Twenty-one medicinal herbs, including Bupleurum chinense, Cinnamomum cassia, and Paeonia lactiflora, were accurately weighed, totaling 230g. For the first decoction, 10 times the weight of the herbs were added to purified water, and the herbs were soaked for 2 hours before decocting for another 2 hours. For the second decoction, 8 times the weight of the herbs were added to water, and the herbs were decocted for 1.5 hours. The two decoctions were combined, filtered, and concentrated to a thick paste with a relative density of 1.1 (60℃). The paste was dried, pulverized, and mixed with dextrin (drug:dextrin = 1:1.1). Granules were then formed using 85% ethanol and dried, resulting in 115g of ready-to-use granules. The same process was used to prepare three batches of granule samples from Example 1. These samples were sealed in clean containers and stored in a cool, dry place for later use.
[0069] 8.2 Three-batch pilot-scale process verification test methods Based on the determined formula and preparation process parameters, three batches of pilot-scale tests were conducted, with the amount produced being 10 times that of the standard prescription. During the granulation process, the ratio of dry extract to dextrin was controlled to be approximately 1:1.1. This process aims to verify the stability and reliability of the process, laying the foundation for mass production and subsequent HPLC fingerprint analysis.
[0070] 8.3 Preparation of reference solution Take appropriate amounts of saikosaponin a, atractylodes lancea, paeonol, and paeoniflorin as reference standards, dissolve them in methanol and dilute to volume to prepare reference solutions with concentrations of 0.4 mg / mL, 20 μg / mL, 20 μg / mL, and 60 μg / mL, respectively; accurately measure 3 μL of cinnamaldehyde and dilute to 10 mL with methanol to prepare a 10 μg / mL solution; take appropriate amounts of glycyrrhizin and ammonium glycyrrhizate as reference standards, dissolve them in 70% ethanol and dilute to volume to prepare reference solutions with concentrations of 20 μg / mL and 0.2 mg / mL, respectively.
[0071] 8.4 Preparation of Sample Test Solution Referring to the methods for the determination of the content of Bupleurum chinense, Cinnamomum cassia, Atractylodes lancea, Paeonia suffruticosa, Paeonia lactiflora, and Glycyrrhiza uralensis in the 2025 edition of the Pharmacopoeia of the People's Republic of China, test solutions for the granular samples of Saikosaponin a, Cinnamaldehyde, Atractylodes lancea, Paeoniflorin, Paeoniflorin, Glycyrrhizin, and Ammonium glycyrrhizate in Example 1 were prepared respectively. The specific procedures are as follows: Saikosaponin A sample test solution: Accurately weigh 2.04 g of granules from Example 1, add 25 mL of methanol solution containing 5% concentrated ammonia, seal tightly, and sonicate for 30 min. Filter, wash the residue with 20 mL of methanol in portions, combine the washings and filtrate, and evaporate to dryness. Add methanol to the residue and bring the volume to 5 mL, shake well, filter, and collect the filtrate.
[0072] Cinnamaldehyde sample test solution: Accurately weigh 1.22 g of particles from Example 1, add 25 mL of methanol, seal tightly and weigh. Sonicate for 30 min, cool and reweigh, make up for weight loss with methanol and shake well. Accurately measure 1 mL of the filter solution, dilute to 25 mL, filter, and the solution is ready.
[0073] Atractylodes lancea sample test solution: Accurately weigh 0.53 g of particles from Example 1, add 25 mL of methanol, seal tightly and weigh. Sonicate for 30 min, cool and reweigh, make up for weight loss with methanol, filter, and collect the filtrate.
[0074] Paeonol sample test solution: Accurately weigh 1.21 g of the particles from Example 1, add 50 mL of methanol, seal tightly and weigh. Sonicate for 30 min, cool and reweigh, then replenish the weight loss with methanol. Accurately measure 1 mL of the filtrate, dilute to 10 mL, filter, and the solution is ready.
[0075] Paeoniflorin sample test solution: Accurately weigh 0.62 g of the particles from Example 1, add 35 mL of dilute ethanol, seal tightly, and sonicate for 30 min. Cool, dilute to the mark with dilute ethanol, shake well, filter, and collect the filtrate.
[0076] Test solution for glycyrrhizin and ammonium glycyrrhizate samples: Accurately weigh 1.13 g of particles from Example 1, add 100 mL of 70% ethanol, seal tightly and weigh. Sonicate for 30 min, cool and reweigh, make up for weight loss with 70% ethanol, filter, and collect the filtrate.
[0077] 8.5 Chromatographic conditions Referring to the HPLC conditions for the determination of index components in Bupleurum, Cinnamon Twig, Atractylodes, Moutan Bark, Peony Root, and Licorice Root in the 2025 edition of the Pharmacopoeia of the People's Republic of China, an Agilent ZORBAX Eclipse XDB-C18 (4.6mm×250mm, 5μm) column was used. The flow rate was set to 1mL / min, the column temperature to 35℃, and the injection volume to 10μL. The contents of saikosaponin a, cinnamaldehyde, atractylodes, paeonol, paeoniflorin, glycyrrhizin, and ammonium glycyrrhizate in the particulate samples of Example 1 were determined as follows.
[0078] Liquid phase conditions for saikosaponin a: Acetonitrile was used as mobile phase A, and water was used as mobile phase B. Gradient elution was performed according to the following program: 0~50 min, phase A increased from 25% to 90%; 50~55 min, phase A was kept at 90% and the detection wavelength was 210 nm.
[0079] Cinnamaldehyde liquid phase conditions: Acetonitrile was used as mobile phase A, water was used as mobile phase B, isocratic elution was used, the mobile phase ratio was A:B=32:68, and the detection wavelength was 290nm.
[0080] Liquid phase conditions for atractylodesin: Methanol was used as mobile phase A, water was used as mobile phase B, isocratic elution was used, the ratio of mobile phases was A:B=79:21, and the detection wavelength was 340nm.
[0081] The liquid chromatography conditions for paeonol were as follows: methanol as mobile phase A, water as mobile phase B, isocratic elution, and a mobile phase ratio of A:B = 45:55. The flow rate was 1 mL / min, the column temperature was 35℃, the injection volume was 10 μL, and the detection wavelength was 274 nm.
[0082] The liquid chromatography conditions for paeoniflorin were as follows: acetonitrile was used as mobile phase A, 0.1% phosphoric acid solution was used as mobile phase B, isocratic elution was used, the ratio of mobile phases was A:B = 14:86, and the detection wavelength was 230 nm.
[0083] Liquid phase conditions for glycyrrhizin and ammonium glycyrrhizate: Acetonitrile was used as mobile phase A, and 0.05% phosphoric acid solution was used as mobile phase B. Gradient elution was performed according to the following program: 0~8 min, maintaining phase A at 19%; 8~35 min, phase A increased from 19% to 50%; 35~36 min, phase A increased from 50% to 100%; 36~40 min, phase A recovered from 100% to 19%. The detection wavelength was 237 nm.
[0084] 9. Experimental Results 9.1 Changes in body weight and food intake like Figure 1 The diagram shown illustrates the changes in mouse body weight after intervention with the finished product prepared in Example 1.
[0085] Table 2. Changes in mouse body weight (g) after intervention following the preparation of the finished product in Example 1. ±s, n = 6)
[0086] Note: # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001 (compared to the Control group); P <0.05, P <0.01, P <0.001, P <0.0001 (compared to the Model group).
[0087] From Table 2 and Figure 1 It was found that the Model group's weight at week 0 (week 6 when prediabetes modeling was successful) was 30.27±2.15g, which was significantly different from the Control group's 24.62±0.53g. During the 10-week treatment period, the Model group's weight maintained a steady upward trend, while the Control group's weight remained between 24 and 25g, maintaining normal metabolic status. Among all treatment groups, the CDF-H group showed the most significant weight control effect compared to the Model group, exhibiting a highly significant difference from week 6. P <0.01%, which was more significant after 7 weeks of administration ( P <0.0001), maintaining highly significant differences at 8-10 weeks of administration. Significant differences appeared between the CDF-L and CDF-M groups starting from 9-10 weeks of administration; the JQJTP group showed a trend toward weight control, but no statistically significant difference was observed.
[0088] like Figure 2 The diagram shown illustrates the changes in food intake in mice after intervention with the finished product prepared in Example 1.
[0089] Table 3. Changes in food intake (g / mouse / day) of mice after intervention following the preparation of the finished product in Example 1 (mean, n = 10)
[0090] To investigate whether the effect of the product prepared in Example 1 on mouse metabolism is related to changes in feeding behavior, the average daily food intake of mice in each group was continuously monitored during the 10-week administration period.
[0091] Combined with Table 3 and Figure 2 The results showed that although the average daily food intake (g / day) of mice in each group fluctuated slightly between different ages, the overall trend remained stable. Compared with the Control group, the physical food intake (g) of mice in the Model group and each intervention group was slightly lower than that of the Control group in the early stage due to the intake of high-energy-density feed, and then remained stable. The difference in average daily food intake among the groups was not statistically significant. The feeding curves of each dose group and the positive control group (JQJTP) in Example 1 highly overlapped with those of the Model group, and were basically maintained in the range of 1.90~2.30 g / day.
[0092] Therefore, in Example 1, the dosage groups did not significantly alter the food intake of mice during the metabolic regulation process. This suggests that the administration process in Example 1 did not affect the feeding behavior of mice; furthermore, the improvement in body weight and metabolic indicators may primarily stem from its promotion of energy expenditure or regulation of nutrient metabolism pathways, rather than from reducing energy intake by suppressing appetite.
[0093] In summary, all dosage groups in Example 1 showed a weight control effect on mice, with the high-dose group showing the best results, maintaining a significant weight control trend from 6 weeks of administration. The medium and low-dose groups began to show differences in weight control from 8 weeks of administration.
[0094] 9.2 Fasting blood glucose and oral glucose tolerance test like Figure 3 The diagram shown illustrates the changes in fasting blood glucose in mice after intervention with the finished product prepared in Example 1. A: Fasting blood glucose curves for each group during the 10-week treatment period; B: Fasting blood glucose in each group at week 10 of treatment.
[0095] Table 4. Changes in fasting blood glucose (mmol / L) in mice after intervention following the preparation of the finished product in Example 1. ±s, n = 6)
[0096] Note: # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001 (compared to the Control group); P <0.05, P <0.01, P <0.001, P <0.0001 (compared to the Model group).
[0097] As shown in Table 4, Figure 3The results showed that at week 0 (week 6) of intervention, the FBG in the Model group was 6.62 ± 0.36 mmol / L, meeting the prediabetic blood glucose criteria and showing a significant difference from the Control group. At week 0, the baseline blood glucose levels in all treatment groups were consistent with those in the Model group. The FBG in the Model group fluctuated and increased throughout the 10 weeks of treatment, exceeding 7.00 mmol / L by weeks 6-8, meeting the diabetic criteria. From week 6 onwards, the FBG levels in all treatment groups showed significant differences compared to the Model group, with the difference further increasing by week 10. The differences between the treatment groups were not significant, with the high-dose group in Example 1 showing the best overall effect. The Control group maintained a normal blood glucose range throughout, and its levels were significantly lower than those in the other groups.
[0098] In summary, after 10 weeks of administration, all dose groups in Example 1 and the JQJTP group significantly reduced fasting blood glucose in mice, with the high-dose group in Example 1 showing the best sustained blood glucose reduction.
[0099] like Figure 4 The diagram shown illustrates the changes in oral glucose tolerance in mice after intervention with the finished product prepared in Example 1. A: OGTT curves for each group; B: Area under the curve for each group.
[0100] Table 5. Changes in oral glucose tolerance (mmol / L) in mice after intervention following the preparation of the finished product in Example 1. ±s, n = 6)
[0101] Note: # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001 (compared to the Control group); P <0.05, P <0.01, P <0.001, P <0.0001 (compared to the Model group).
[0102] Ten weeks after administration, all mice underwent an oral glucose tolerance test (OGTT). See Table 5. Figure 4The results showed that, compared with the Control group, the blood glucose levels in the Model group were significantly different at multiple time points. Compared with the Model group, the OGTT curves and AUC areas of all treatment groups were lower or smaller than those of the Model group. The CDF-L group showed differences at the 30-minute and 60-minute time points; the CDF-H group and the JQJTP group showed differences at the 60-minute time point. The overall AUC area was significantly smaller in the CDF-L group than in the Model group.
[0103] In summary, the product prepared in Example 1 can improve glucose intolerance in mice to some extent, but only the low-dose group showed statistical differences and did not exhibit typical dose-response characteristics.
[0104] 9.3 Insulin resistance like Figure 5 The diagram shown illustrates the changes in insulin resistance in mice after intervention with the product prepared in Example 1. In the diagram, A represents fasting serum insulin; B represents the insulin resistance index; and C represents the pancreatic β-cell function index.
[0105] Table 6. Changes in insulin resistance in mice after intervention following the preparation of the finished product in Example 1 ( ±s, n = 6)
[0106] Note: # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001 (compared to the Control group); P <0.05, P <0.01, P <0.001, P <0.0001 (compared to the Model group).
[0107] As shown in Table 6, Figure 5 The results showed that, compared with the control group, the fasting insulin level and insulin resistance index (HOMA-IR) of the model group were significantly higher. PThe HOMA-β index (<0.0001) was slightly lower than that of the Control group (the highest HOMA-β index in the Control group may be related to the low FBG in mice), but it was still at a relatively high level. This indicates that the diabetic mouse model has developed significant insulin resistance. After drug intervention, compared with the model group, all dose groups (low, medium, and high) and the positive control group in Example 1 reduced fasting insulin, HOMA-IR, and HOMA-β levels to varying degrees. Among them, the high-dose group and the positive control group showed more significant improvement in insulin resistance, with the high-dose group showing the best improvement. In addition, regarding the HOMA-β index, all treatment groups showed a decreasing trend compared with the Model group. Although there was no statistically significant difference, it also alleviated the compensatory burden of excessive insulin secretion by pancreatic β cells to some extent.
[0108] In summary, Example 1 can effectively alleviate insulin resistance in mice, with the high-dose group showing the most significant effect, and it also has a certain protective and improving effect on pancreatic β-cell function.
[0109] 9.4 Blood lipids like Figure 6 The diagram shown illustrates the changes in blood lipids in mice after intervention with the finished product prepared in Example 1. In the diagram, A represents triglycerides; B represents total cholesterol; C represents low-density lipoprotein cholesterol; and D represents high-density lipoprotein cholesterol.
[0110] Table 7. Changes in blood lipids (mmol / L) in mice after intervention following the preparation of the finished product in Example 1. ±s, n = 6)
[0111] Note: # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001 (compared to the Control group); P <0.05, P <0.01, P <0.001, P <0.0001 (compared to the Model group).
[0112] As shown in Table 7, Figure 6 The results showed that, compared with the control group, the Model group exhibited significantly elevated levels of TG, TC, and LDL-C, indicating a marked lipid metabolism disorder in the diabetic mouse model. After drug intervention, compared with the Model group, all CDF dose groups significantly reduced TG, TC, and LDL-C levels, with the high-dose group showing the most significant lipid-lowering effect. Simultaneously, all CDF dose groups and the positive control group significantly reversed the decrease in HDL-C, promoting a significant recovery in its level. Furthermore, the positive control group also showed significant efficacy in improving TG and LDL-C levels. In summary, Example 1 effectively regulates dyslipidemia in mice and significantly improves their lipid metabolism disorder.
[0113] 9.5 Liver function like Figure 7 The diagram shown illustrates the changes in liver function in mice after intervention with the finished product prepared in Example 1. In this diagram, A represents alanine aminotransferase (ALT), and B represents aspartate aminotransferase (AST).
[0114] Table 8. Changes in liver function in mice after intervention following the preparation of the finished product in Example 1 ( ±s, n = 6)
[0115] Note: # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001 (compared to the Control group); P <0.05, P <0.01, P <0.001, P <0.0001 (compared to the Model group).
[0116] As shown in Table 8, Figure 7The results showed that, compared with the control group, the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), indicators of liver damage, were significantly elevated in the model group mice, indicating that the diabetic model mice had significant liver function impairment. After drug intervention, compared with the model group, all CDF dose groups and the positive control group significantly reduced ALT and AST levels, demonstrating a significant improvement effect. In summary, Example 1 effectively alleviated the accompanying liver function damage in mice while improving the diabetic state, thus exerting a protective effect on target organs.
[0117] 9.6 Serum inflammatory factors like Figure 8 The diagram shown illustrates the changes in serum inflammatory factors in mice after intervention with the product prepared in Example 1. Wherein, A: TNF-α; B: IFN-γ; C: IL-6; D: IL-1β; E: IL-12p70; F: IL-17A; G: IL-2; H: IL-4; I: IL-5; J: IL-10.
[0118] Table 9. Changes in inflammatory factors (pg / mL) in mice after intervention following the preparation of the finished product in Example 1. ±s, n = 6)
[0119] Note: # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001 (compared to the Control group); P <0.05, P <0.01, P <0.001, P <0.0001 (compared to the Model group).
[0120] As shown in Table 9, Figure 8 The results showed that, compared with the control group, the levels of pro-inflammatory factors in the serum of mice in the model group were significantly upregulated, including TNF-α, IFN-γ, IL-6, IL-1β, IL-12p70, and IL-17A.P <0.001 or P <0.0001), demonstrating a strong systemic inflammatory response in diabetic model mice. In Example 1, after intervention at each dosage group, the excessive secretion of the aforementioned pro-inflammatory factors was effectively inhibited. Particularly in the regulation of TNF-α, IL-6, IL-1β, IL-12p70, and IL-17A, each dosage group showed a highly significant downregulation effect (…). P <0.01 or P <0.0001). The positive control group (JQJTP) also significantly reduced the levels of these pro-inflammatory factors.
[0121] Regarding changes in cytokines with anti-inflammatory or immunomodulatory functions ( Figure 8 In the Model group, serum levels of IL-2, IL-4, IL-5, and IL-10 were significantly lower than those in the Control group, suggesting impaired anti-inflammatory compensation mechanisms in diabetic mice. In Example 1, after intervention in each dose group, the levels of these factors were restored to varying degrees. Among them, the high-dose group significantly upregulated IL-2 levels (GJ). P <0.0001); the medium and high dose groups significantly increased the levels of IL-4 and IL-5 ( P <0.05 or P <0.01); while the low-dose group showed a significant effect on the recovery of IL-10 ( P <0.05).
[0122] The above results indicate that Example 1 can effectively correct the immune imbalance and systemic inflammatory state in diabetic mice through a bidirectional regulatory mechanism, namely, simultaneously inhibiting the pro-inflammatory cascade reaction and restoring the level of anti-inflammatory factors.
[0123] 9.7 Liver Pathology like Figure 9 The image shows photographs of liver samples taken from mice in each group, along with schematic diagrams of HE staining and Oil Red staining results.
[0124] Results combined Figure 9As can be seen from the HE and Oil Red staining results of the liver, the control group mice showed intact liver lobule structure, radially arranged hepatocytes, abundant cytoplasm, and no lipid deposition. In contrast, the model group exhibited severe non-alcoholic fatty liver disease (NAFLD) characteristics, with hepatocytes filled with numerous fat vacuoles of varying sizes (HE staining), and Oil Red O staining revealing large areas of bright red lipid droplets merging into a network, accompanied by significant hepatocyte ballooning degeneration and mild intralobular inflammation. With increasing drug dosage, the number of fat vacuoles and red lipid droplets in hepatocytes gradually decreased. Although the low-dose group showed improvement, a relatively large amount of lipids remained; the improvement effects were particularly significant in the medium and high-dose groups, with the liver tissue morphology of the high-dose group basically returning to normal and lipid droplets almost disappearing. The positive control group also showed good protective effects, with lipid levels comparable to the medium-dose group. These results indicate that Example 1 can effectively inhibit steatosis in the liver of diabetic mice and repair tissue damage.
[0125] 9.8 Results of determination of index component content in Example 1 9.8.1 Separation of Indicative Components like Figure 10 The figure shows the high-performance liquid chromatograms of the test solution and the reference solution of the particulate sample in Example 1.
[0126] Results combined Figure 10 It can be seen that, under the aforementioned chromatographic conditions, the indicative components of saikosaponin a, cinnamaldehyde, atractylodes, paeonol, paeoniflorin, glycyrrhizin and glycyrrhizic acid ammonium in the particulate sample of Example 1 were well separated and had retention times consistent with the corresponding reference standards.
[0127] 9.8.2 Content determination results According to the aforementioned sample preparation method, test solutions for each sample were prepared, and the samples were injected and determined under the corresponding chromatographic conditions. The content of the corresponding index components in the test solutions of the particulate samples of Example 1 was calculated using the external standard one-point method. The results are shown in Table 10.
[0128] Table 10 Content (%) of each indicative component
[0129] 10. Conclusion The above pharmacodynamic experimental results show that the traditional Chinese medicine composition provided by the present invention (Example 1) can: (1) significantly control the weight gain of prediabetic mice; (2) significantly reduce fasting blood glucose and improve oral glucose tolerance; (3) significantly improve insulin resistance; (4) significantly regulate dyslipidemia; (5) significantly improve liver function damage; (6) effectively regulate serum inflammatory factor levels, inhibit excessive secretion of pro-inflammatory factors and restore anti-inflammatory factor levels; and (7) significantly inhibit hepatic steatosis.
[0130] The above results indicate that the present invention has a significant overall regulatory effect on metabolic syndrome and is suitable for long-term intervention in prediabetes of the middle-dose type with internal heat.
[0131] Finally, it should be noted that the above description is merely a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. A traditional Chinese medicine composition for improving prediabetes of the type characterized by fullness and internal heat, characterized in that, Composed of the following parts by weight of active pharmaceutical ingredient: Bupleurum chinense 8-16 parts, Cinnamomum cassia 7-13 parts, Paeonia lactiflora 7-13 parts, Trichosanthes kirilowii 7-13 parts, Allium macrostemon 7-13 parts, Citrus aurantium 7-13 parts, Atractylodes lancea 7-13 parts, Citrus reticulata 7-13 parts, Magnolia officinalis 7-13 parts, Atractylodes macrocephala 7-13 parts, Poria cocos 7-13 parts, Polyporus umbellatus 7-13 parts, Alisma plantago-aquatica 7-13 parts, Rehmannia glutinosa 20-40 parts, Paeonia suffruticosa 7-13 parts, Glycyrrhiza uralensis 7-13 parts, Zingiber officinale 3-7 parts, Coptis chinensis 7-13 parts, Cinnamomum cassia 2-4 parts, Astragalus membranaceus 10-20 parts, and Pueraria lobata 10-20 parts.
2. The traditional Chinese medicine composition for improving prediabetes of the type with internal heat and fullness according to claim 1, characterized in that, Composed of the following parts by weight of active pharmaceutical ingredient: Bupleurum chinense 12 parts, Cinnamomum cassia 10 parts, Paeonia lactiflora 10 parts, Trichosanthes kirilowii 10 parts, Allium macrostemon 10 parts, Citrus aurantium 10 parts, Atractylodes lancea 10 parts, Citrus reticulata 10 parts, Magnolia officinalis 10 parts, Atractylodes macrocephala 10 parts, Poria cocos 10 parts, Polyporus umbellatus 10 parts, Alisma plantago-aquatica 10 parts, Rehmannia glutinosa 30 parts, Paeonia suffruticosa 10 parts, Glycyrrhiza uralensis 10 parts, Zingiber officinale 5 parts, Coptis chinensis 10 parts, Cinnamomum cassia 3 parts, Astragalus membranaceus 15 parts, and Pueraria lobata 15 parts.
3. A preparation for improving prediabetes of the type characterized by internal heat and fullness, characterized in that, It is prepared from the traditional Chinese medicine composition as described in claim 1 or 2.
4. A method for preparing the formulation for improving prediabetes of the central nervous system type as described in claim 3, characterized in that, Includes the following steps: S1. Pretreatment and Grinding: Weigh each raw material according to the formula, clean and remove impurities, dry and mix evenly, then pulverize and set aside. S2, Extraction: Place the weighed raw materials in an extraction container, add 6 to 12 times the total weight of the medicinal materials in water, soak for 0.5 to 2.5 hours, heat to boiling, and simmer for 1.5 to 2.5 hours. Filter and collect the first extract. Add 4 to 8 times the total weight of the medicinal materials in water to the dregs again, continue to simmer for 1 to 2 hours, and filter and collect the second extract. S3. Concentration and Drying: Combine the two extracts, allow them to stand and precipitate, take the supernatant or filter, concentrate the filtrate to a thick paste or clear paste with a relative density of 1.10 to 1.20 under conditions of -0.08 to -0.06 MPa and 50 to 70℃, and spray dry it with an inlet air temperature of 160 to 190℃ and an outlet air temperature of 70 to 85℃ to obtain dry extract powder; S4, Molding: The dry extract powder is mixed with excipients, a wetting agent is added to form a soft material, which is then granulated, dried, and sized to obtain the final product.
5. The preparation method according to claim 4, characterized in that, In step S1, the material is pulverized and then passed through an 80-100 mesh sieve. In step S2, the first decoction is prepared by adding 10 times the amount of water, soaking for 2 hours, and then decocting for 2 hours; the second decoction is prepared by adding 8 times the amount of water and decocting for 1.5 hours.
6. The preparation method according to claim 4, characterized in that, In S4, the excipients include any one of dextrin, starch, and lactose; The dry extract powder and excipients are mixed at a mass ratio of 1:0.8~1.2; The wetting agent is ethanol with a mass fraction of 70-90%; The granulation process involves passing the pellet through a 12-14 mesh filter sieve. The drying temperature is 55~65℃.
7. The use of the formulation for improving prediabetes of the type with internal heat as described in claim 3 in the preparation of a drug for improving prediabetes symptoms.
8. The application according to claim 7, characterized in that, The improvement of prediabetic symptoms includes reducing fasting blood glucose in prediabetic mice, improving oral glucose tolerance, regulating dyslipidemia, controlling weight gain, improving insulin resistance and liver function damage, and regulating serum inflammatory factor levels.
9. The application according to claim 8, characterized in that, The regulation of serum inflammatory factor levels includes inhibiting the excessive secretion of pro-inflammatory factors such as TNF-α, IL-6, IL-1β, IL-12p70, and IL-17A; and restoring the levels of anti-inflammatory factors such as IL-2, IL-4, IL-5, and IL-10.
Citation Information
Patent Citations
Pharmaceutical composition for treating diabetes mellitus in earlier stage
CN108186636A
Traditional Chinese medicine composition for treating prediabetes and application thereof
CN114392319A
Composition for treating type 2 diabetes mellitus and prediabetes mellitus and preparation method thereof
CN117137989A
Traditional Chinese medicine composition for treating prediabetes as well as preparation method and application of traditional Chinese medicine composition
CN120437227A
